Literature DB >> 21295418

Routine Lactobacillus rhamnosus GG administration in VLBW infants: a retrospective, 6-year cohort study.

Paolo Manzoni1, Gianluca Lista, Elena Gallo, Paola Marangione, Claudio Priolo, Paola Fontana, Roberta Guardione, Daniele Farina.   

Abstract

BACKGROUND: In preterm neonates, use of probiotic mixtures is increasingly popular and is effective in preventing NEC, fungal colonization, and improving feeding tolerance. However, concerns exist about safety and tolerability of long-lasting administration of living microrganisms to not-immunocompetent hosts. We report a 6-year, two-NICUs experience of routinary Lactobacillus rhamnosus GG (LGG) use in VLBW infants.
METHODS: Clinical charts review, retrospective study of VLBW infants admitted to two Italian NICUs in the years 2003-2008. Standard protocol of LGG administration consisted of 3 x 10⁹ CFU/day, in single oral dose, since 4th day-of-life, for 4-to-6-week courses. Nutritional policy relied on administration of fresh, expressed mother's milk, supplementation with preterm formula if needed. Data about LGG safety and tolerability, infections, feeding tolerance, microbiological clinical and surveillance cultures were retrieved and analysed.
RESULTS: Complete data were obtained for 743 of 811 VLBW infants. Mean birth-weight was 1056 g; mean gestational age 29.5 weeks. A total of 17,108 LGG doses were administered (mean 23.1/infant). No adverse effects or intolerances putatively attributable to LGG occurred. Overall, 5350 clinical and surveillance cultures from 13 different sites/devices were performed (mean: 7.2 cultures from 6.5 different sites/infant). None ever grew LGG, or other Lactobacilli. No clinical sepsis episode was attributable to LGG. Full enteral feeding was achieved at 19.2 mean days-of-life; 73% of infants were exclusively/partially breastfed. Fourteen NEC cases occurred (=1.9%), with 5 (=0.7%) being>2b stage.
CONCLUSIONS: Routinary supplementation of probiotic LGG in a large, 6-year VLBW infants Italian cohort proved microbiologically safe and clinically well tolerated.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21295418     DOI: 10.1016/j.earlhumdev.2011.01.036

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  12 in total

1.  Routine Supplementation of Lactobacillus rhamnosus GG and Risk of Necrotizing Enterocolitis in Very Low Birth Weight Infants.

Authors:  Andrea F Kane; Anisha D Bhatia; Patricia W Denning; Andi L Shane; Ravi Mangal Patel
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

Review 2.  Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.

Authors:  William E Bennett
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

Review 3.  Facultative to strict anaerobes ratio in the preterm infant microbiota: a target for intervention?

Authors:  Silvia Arboleya; Gonzalo Solís; Nuria Fernández; Clara G de los Reyes-Gavilán; Miguel Gueimonde
Journal:  Gut Microbes       Date:  2012-08-24

4.  Probiotics and Innate and Adaptive Immune Responses in Premature Infants.

Authors:  Mark A Underwood
Journal:  For Immunopathol Dis Therap       Date:  2016

5.  Gut microbial translocation in critically ill children and effects of supplementation with pre- and pro biotics.

Authors:  Paola Papoff; Giancarlo Ceccarelli; Gabriella d'Ettorre; Carla Cerasaro; Elena Caresta; Fabio Midulla; Corrado Moretti
Journal:  Int J Microbiol       Date:  2012-08-15

Review 6.  Towards a better understanding of Lactobacillus rhamnosus GG--host interactions.

Authors:  Marijke E Segers; Sarah Lebeer
Journal:  Microb Cell Fact       Date:  2014-08-29       Impact factor: 5.328

Review 7.  Probiotics in critically ill children.

Authors:  Sunit C Singhi; Suresh Kumar
Journal:  F1000Res       Date:  2016-03-29

8.  Long-term safety assessment in children who received hydrolyzed protein formulas with Lactobacillus rhamnosus GG: a 5-year follow-up.

Authors:  Dmf Scalabrin; C Harris; W H Johnston; C L Berseth
Journal:  Eur J Pediatr       Date:  2016-12-15       Impact factor: 3.183

9.  Harnessing microbiome and probiotic research in sub-Saharan Africa: recommendations from an African workshop.

Authors:  Gregor Reid; Nicholas Nduti; Wilbert Sybesma; Remco Kort; Tobias R Kollmann; Rod Adam; Hamadi Boga; Eric M Brown; Alexandra Einerhand; Hani El-Nezami; Gregory B Gloor; Irene I Kavere; Johanna Lindahl; Amee Manges; Wondu Mamo; Rocio Martin; Amy McMillan; Jael Obiero; Pamela A Ochieng'; Arnold Onyango; Stephen Rulisa; Eeva Salminen; Seppo Salminen; Antony Sije; Jonathan R Swann; William van Treuren; Daniel Waweru; Steve J Kemp
Journal:  Microbiome       Date:  2014-04-16       Impact factor: 14.650

10.  Antifungal defense of probiotic Lactobacillus rhamnosus GG is mediated by blocking adhesion and nutrient depletion.

Authors:  Daniela Mailänder-Sánchez; Christina Braunsdorf; Christian Grumaz; Christoph Müller; Stefan Lorenz; Philip Stevens; Jeanette Wagener; Betty Hebecker; Bernhard Hube; Franz Bracher; Kai Sohn; Martin Schaller
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.